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Abstract
Background: Pierre-Robin sequence (PRS) is defined by micro- and/or retrognathia, glossoptosis and cleft soft
palate, either caused by deformational defect or part of a malformation syndrome. Neurofibromatosis type 2 (NF2)
is an autosomal dominant syndrome caused by mutations in the NF2 gene on chromosome 22q12.2. NF2 is
characterized by bilateral vestibular schwannomas, spinal cord schwannomas, meningiomas and ependymomas,
and juvenile cataracts. To date, NF2 and PRS have not been described together in the same patient.
Case presentation: We report a female with PRS (micrognathia, cleft palate), microcephaly, ocular hypertelorism,
mental retardation and bilateral hearing loss, who at age 15 was also diagnosed with severe NF2 (bilateral
cerebellopontine schwannomas and multiple extramedullary/intradural spine tumors). This is the first published
report of an individual with both diagnosed PRS and NF2. High resolution karyotype revealed 46, XX, del(22)
(q12.1q12.3), FISH confirmed a deletion encompassing NF2, and chromosomal microarray identified a 3,693 kb
deletion encompassing multiple genes including NF2 and MN1 (meningioma 1).
Five additional patients with craniofacial dysmorphism and deletion in chromosome 22-adjacent-to or containing
NF2 were identified in PubMed and the DECIPHER clinical chromosomal database. Their shared chromosomal
deletion encompassed MN1, PITPNB and TTC28. MN1, initially cloned from a patient with meningioma, is an
oncogene in murine hematopoiesis and participates as a fusion gene (TEL/MN1) in human myeloid leukemias.
Interestingly, Mn1-haploinsufficient mice have abnormal skull development and secondary cleft palate. Additionally,
Mn1 regulates maturation and function of calvarial osteoblasts and is an upstream regulator of Tbx22, a gene
associated with murine and human cleft palate. This suggests that deletion of MN1 in the six patients we describe
may be causally linked to their cleft palates and/or craniofacial abnormalities.
Conclusions: Thus, our report describes a NF2-adjacent chromosome 22q12.2 deletion syndrome and is the first to
report association of MN1 deletion with abnormal craniofacial development and/or cleft palate in humans.
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Pierre-Robin sequence (PRS) refers to a combination of
micrognathia or retrognathia, glossoptosis and respira-
tory distress, with or without cleft palate, named after
the French stomatologist, Pierre Robin [1-5]. The inci-
dence of PRS is estimated at 1 in 8,500-14,000 births
and continues to be associated with high morbidity sec-
ondary to a compromised airway, feeding difficulties,
and speech problems [6-9]. While the clinical presenta-
tion is well defined, pathogenesis is heterogeneous and
not completely understood. In half or more of patients
PRS occurs in isolation [2,4,5,7]. Isolated PRS is often
thought to be due to intrauterine fetal constraint where
extrinsic physical forces (e.g., oligohydramnios, breech
position or abnormal uterine anatomy) inhibit normal
mandibular growth. Micrognathia in early fetal develop-
ment may then cause the tongue to remain between the
palatal shelves, thus interfering with palate closure
[2,10]. However, this mechanism has been challenged by
some [11]. Isolated PRS can also be associated with
chromosomal deletions such as 2q24.1-33.3, 4q32-qter,
11q21-23.1, and 17q21-24.3 [6]. Recent reports of iso-
lated PRS have additionally found mutations in highly
conserved non-coding elements surrounding SOX9 at
17q24 [6,12,13]. Frequently, PRS is associated with addi-
tional clinical findings that may or may not constitute
part of a recognized syndrome. The most common PRS-
associated syndromes include Stickler syndrome, velo-
cardio-facial syndrome (VCFS, associated with chromo-
some 22q11.2 mutations), fetal alcohol syndrome and
trisomy 18 [3-5].
Neurofibromatosis type 2 (NF2) is an autosomal
dominant disorder that predisposes to multiple neoplas-
tic lesions. Birth incidence is estimated to be between 1
in 25,000 to 1 in 40,000 births [14-18]. The distinctive
features of NF2 are eighth cranial nerve schwannomas,
which occur bilaterally in over 90% of NF2 patients
[14,16,19]. Patients may also develop schwannomas in
other locations, particularly the spine, as well as menin-
giomas, ependymomas, and juvenile cataracts. NF2 is
typically caused by truncating mutations (nonsense or
frameshift) of the NF2 gene on chromosome 22q12.2,
which encodes the intracellular membrane-associated
tumor suppressor protein, merlin, also called schwanno-
min [20-23]. While most NF2 patients are diagnosed in
their second or third decades of life, cataract, hearing
loss, facial weakness, headache or ataxia may occur dur-
ing childhood.
To date, there have been no published reports of
patients diagnosed with both PRS and NF2. Here we
provide the first description of clinical association
between PRS (including cleft palate) and NF2 in a
patient in whom we found a 22q12.2 deletion.
Interestingly in addition to NF2, this deletion also
encompasses Meningioma1 (MN1), a gene that is impor-
tant in murine craniofacial development, and whose
haploinsufficiency in mice causes skull abnormalities
and secondary cleft palate, but which to date, has not
been associated with malformations in humans.
Case presentation
Our patient (PRS-NF2) was born to healthy non-consan-
guineous parents (mother 39 years old) at week 36 by
emergency cesarean section due to premature contrac-
tions and early decelerations. Pregnancy was otherwise
uncomplicated, without report of oligohydramnios or
breech presentation. Cleft palate, micrognathia, microce-
phaly and ocular hypertelorism were noted at birth and
the patient suffered multiple apneic episodes. For the
first year she was fed by nasogastric tube due to poor
weight gain. Motor development was delayed (rolled at
8 months, sat at 10 months, walked at 18 months), and
she was later diagnosed with mental retardation. From
preschool age she had bilateral severe conductive hear-
ing loss requiring hearing aids that was attributed to
bony changes associated with her congenital dysmorphic
features. Sensorineural hearing was only mildly affected
at that time. At age 14 she had severe to profound
mixed hearing loss to which the bony conductance only
contributed mild to moderate impairment. Her dys-
morphic features, including micrognathia and hyperte-
lorism, persisted into early adulthood and are shown in
Figure 1A-B.
At age 15 years PRS-NF2 presented for the first time
with a 2 week history of headache and ataxia. Brain
MRI showed bilateral large acoustic masses and a left
trigeminal mass (Figure 1C-D). Corpus callosum was
normal. Spine MRI showed multiple extramedullary
intradural lesions ranging from 1 to 7 mm in diameter
(approximately 12 lesions identified from the C4-C5
level to the cauda equina; Figure 1E-F). A left-sided C7-
T1 extradural lesion and a separate left-sided C7-T1
neurofibroma were also seen, and increased in size in
subsequent years. No definite intramedullary lesions
were identified. A holocord syrinx, likely related to a
secondary Chiari malformation (inferior cerebellar tonsil
herniation), was also evident. The left cerebellopontine
tumor was partially-resected and identified as a schwan-
noma, consistent with diagnosis of NF2 (Figure 1G-H).
Hence, we designated her as patient PRS-NF2. The high
tumor burden, tumor progression and the patient’s
young age at onset of tumors fit a classification of severe
NF2 [14,21-25].
Due to the unique combination of severe NF2, facial
dysmorphism and mental retardation in patient PRS-
NF2, genetic evaluation was initiated. G-banding high
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Page 2 of 8Figure 1 Patient PRS-NF2, clinical presentation. A-B) PRS-NF2 at age 17 years with severe micrognathia, ocular hypertelorism and
microcephaly. Measurements: outer canthal distance 8.3 cm, 25
th %ile; inner canthal distance 4 cm, 3 S.D. above the mean; interpupillary
distance 5.5 cm, 25
th %ile; head circumference 52 cm, 2
nd %ile, weight 41.8 kg, 2-1.4 S.D. below the mean; height 156 cm, 10
th-25
th %ile. C-D)
MRI of brain shows bilateral cerebellopontine angle tumors (left: 3.1 × 4.6 × 6.1 cm, right: 1 × 1.2 × 1.1 cm; arrows) with mass effect by the left
tumor on the brain stem, pons and cerebellum, with associated effacement of the 4
th ventricle, enlargement of the 3
rd and lateral ventricles,
enlarged cervical cord and tonsillar herniation. E-F) MRI of spine shows holocord syrinx with large neurofibroma at C7-T1 (E), causing cord
compression and canal stenosis. Some of the other extramedullary intradural neurofibromas described in the text are also shown. G-H)
Histological analysis of the resected left cerebellopontine angle tumor shows spindled nuclei with dense to finely granular chromatin and cells
with long tapering cytoplasmic processes with inconspicuous outer membranes. Panel G demonstrates both short fascicular bundles with dense
Antoni type A area (right upper corner) and loose hypocellular Antoni type B area (middle to left lower corner) characteristic of schwannomas
(H&E, G-100×). Panel H is 400 × magnification of the inset from panel G).
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Page 3 of 8resolution karyotype on her blood revealed 46, XX, del
(22)(q12.2), indicative of an interstitial deletion of band
q 1 2 . 2i nt h el o n ga r mo fc h r o m o s o m e2 2( F i g u r e2 A ,
arrow). FISH demonstrated a deletion of at least 1,607
kb in the 22q12.2 region (Figure 2B). Parental testing
was declined. Chromosomal microarray analysis (CMA;
Affymetrix SNP 6.0 array) to better delineate the muta-
tion detected a chromosome 22q12.2 deletion of
approximately 3.7 Mb (3,693 kb) spanning the NF2
gene, with break points at base pairs 25937541 and
29635842 (UCSC Genome Browser version hg18, release
name NCBI build 36.1) (Figure 2C).
Discussion
This is the first published report of a patient diagnosed
with both PRS and NF2. Our patient’s diagnosis of PRS,
based on micrognathia and cleft palate, represents only
part of her phenotype, which also includes microce-
phaly, ocular hypertelorism and mental retardation.
Molecular analysis revealed a 22q12.2 deletion spanning
approximately 3.7 Mb and encompassing the NF2 gene
locus. The chromosomal microdeletion associated with
velo-cardio-facial syndrome (22q11.2 locus) was intact
in our patient. Therefore, we propose that we have iden-
tified a novel NF2-adjacent 22q12.2 microdeletion
syndrome.
Review of the literature revealed only five other
patients who presented with clinical features distinct
from the standard diagnostic criteria of NF2 [24,26] and
who had large 22q12 deletions encompassing the NF2
gene (Table 1, Figure 3). Of these five patients three are
described by Bruder et al [19,27]. The first (JP) had a
7.4 Mb deletion of chromosome 22q12, bilateral vestibu-
lar schwannomas before the age of 25 years, mental
Figure 2 3,693 kb deletion of 22q12.2 in patient PRS-NF2. A) G-banding high resolution karyotype reveals interstitial deletion of the light
band q12.2 in the long arm of chromosome 22 (arrowhead - intact normal region; arrow - deleted region). B) Fluorescence in situ hybridization
(FISH) studies with EWSR1 (22q12.2) dual color break apart probe revealed one entire fusion signal missing indicating heterozygous deletion in
22q12.2. FISH studies with flanking probes: TUPLE1 (22q11.2) and the BCR(22q11.2)/ABL(9q34) probes showed no deletions of TUPLE or BCR. C)
Affymetrix Genotyping Console™ (GTC) Software display of the 22q12.2 deletion identified using chromosomal microarray (CMA; Affymetrix
Genome-wide Human SNP Array 6.0).
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Page 4 of 8retardation, and grand mal seizure at age 9 years, but no
report of facial dysmorphism [19]. A second patient
(p41) had NF2, facial dysmorphic features, mental retar-
dation, developmental delay and a large 22q12 deletion
with unknown span due to an unclear proximal deletion
breakpoint [27]. The third patient (p12) had moderate
NF2, mild mental retardation, and a 530 kb deletion
encompassing NF2 [27]. Two other described patients,
pX and TC, with large deletions at chromosome 22q12
that included NF2 also had severe craniofacial dys-
morphism, but were too young to show stigmata of NF2
[28,29]. The first was a 10.5 month old female (pX) with
facial dysmorphism including hypertelorism, mandibular
hypoplasia, cleft palate, severe neurodevelopmental delay
and 8 Mb deletion of chromosome 22q12.2-q12.3 [28].
Her mandibular hypoplasia and cleft palate suggest
likely diagnosis of PRS. The second young patient (TC)
had Toriello-Carey syndrome, including PRS with large
Table 1 Patient phenotypes.
Clinical features
Patient NF2 Cleft palate or craniofacial
dysmorphism
MR Other described findings
PRS-
NF2
Yes Cleft palate Microcephaly Yes Micrognathia, hypertelorism, conductive hearing loss. Corpus callosum and cardiac
evaluation were normal.
TC [29] ? * Cleft palate ?
**
Micrognathia, hypertelorism, absent corpus callosum, cardiac defects,
pX [28] ? * Cleft palate Yes Mandibular hypoplasia, hypertelorism
p41
[27]
Yes Facial dysmorphism Yes Cerebral paresis, pes cavus, peripheral facial paresis, cerebral movement disorder,
cataracts
JP [19] Yes - Yes Seizure disorder
p12
[27]
Yes - Yes
999 [30] - Microcephaly Yes Speech delay
4110
[30]
- Cleft palate Yes Auricular pits, cataracts, deafness, hypotonia, proptosis, short phalanges
Clinical features of the eight patients described in the text [19,27-30]
* Patients pX and TC were was only 10 months old and 2 years old, respectively, at the time of the report [28,29]. While their clinical description did not include
features of NF2, as would be expected at their age, their deletions did encompass the NF2 gene.
** Patient TC was described as having walked at age 22 months, but there is insufficient information to determine other measures of developmental and/or
intellectual delay.
NF2 neurofibromatosis 2, MR mental retardation.
Figure 3 Chromosome 22q12.2 deletions reveal loss of MN1 in six patients with facial dysmorphism and/or cleft palate and/or
abnormal cranium. Schema of the deletions on chromosome 22q12.2 in the eight patients described in the text and Table 1. Black bars depict
the six patients with abnormal cranium and/or facial dysmorphism, and/or cleft palate. pX and TC were too young to determine whether they
manifest clinical NF2. Gray bars depict the two patients without these abnormalities but with NF2. Dashed black line indicates the approximated
proximal deletion in patient p41. Genes: NF2-purple, TTC28-green, PITPNB-orange, MN1-blue. Translucent vertical bars align the location of the
deleted genes in relation to the chromosomal deletion found in each patient.
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Page 5 of 8cleft palate, micrognathia, hypertelorism, agenesis of the
corpus callosum, and 6 Mb deletion overlapping much
of the deletion of pX and PRS-NF2 [29]. Patient TC
only walked at 22 months [29].
The young age at which PRS-NF2 was diagnosed with
bilateral vestibular schwannomas (15 years), the high
tumor burden that included multiple spinal tumors, and
the progressive nature of some of these tumors qualify
her as having a severe form of NF2 [14,23,24]. Several
reports have demonstrated that nonsense/frameshift
mutations are associated with a more severe phenotype
than are deletions of the NF2 gene. This difference is
thought to be due to nonsense/frameshift mutations
causing a truncated protein that may have dominant
negative effect, versus deletion of one copy of the NF2
gene, that results in decreased merlin protein expression
[14,22,23,31]. Watson et al provided the first report on
a large deletion (600-700 kb) encompassing NF2 that
was associated with mild disease without mental retar-
dation or facial dysmorphism [32]. Bruder et al
described patient p12, who had a 530 kb deletion
encompassing NF2 (partially overlapping with the
patient reported by Watson et al) and who had moder-
a t eN F 2[ 2 7 ]( F i g u r e3 ,T a b le 1). Others support that
complete deletion of the NF2 gene is usually associated
with mild disease [33-35]. It is therefore interesting that
PRS-NF2 (our patient) and patient JP [19], both of
whom had large deletions encompassing the NF2 gene,
had severe NF2 phenotype (Figure 3). Bruder et al
hypothesized that the high severity of NF2 in JP may be
due to loss of a putative second tumor suppressor gene
within the 7.4 Mb deletion, that usually remained intact
in patients with smaller chromosomal deletions that
encompass all of NF2 [19]. Deletion of this putative
tumor suppressor may have similarly changed a gener-
ally mild phenotype associated with complete deletion
of NF2 to the severe phenotype seen in PRS-NF2.
The craniofacial dysmorphism in PRS-NF2 and the
three other patients whose deletion overlaps her deletion
(pX, p41, TC; Table 1, Figure 3) suggested a causal link
between loss of one or more genes within the overlap-
ping region of the NF2-adjacent 22q12.2 deletion and
these clinical findings. To further investigate this asso-
ciation we searched the public database DECIPHER,
which contains clinical information of individuals with
chromosomal anomalies with the aim of increasing
medical and scientific knowledge about these chromoso-
mal defects [30]. DECIPHER reported two patients with
chromosomal deletions in the region deleted in PRS-
NF2 (Figure 3, patients 4110 and 999). Although the
information is brief, there are similarities to PRS-NF2,
pX, p41 and TC (Table 1): Both 4110 and 999 had men-
tal retardation; patient 4110 had a submucous cleft
palate and patient 999 had speech delay and
microcephaly.
To determine genes potentially associated with the
craniofacial dysmorphism and/or palatal defects in these
six patients we aligned their deletions (Figure 3). The
deleted area common to all six patients includes three
recognized genes: MN1, PITPNB and TTC28,n o n eo f
which has been previously linked in humans to palatal
defects, calvarial abnormalities or craniofacial dysmorph-
ism. Of these, MN1, initially reported as a candidate
gene for sporadic meningioma and later found to be
involved in acute myeloid leukemia (fusion TEL/MN1)
and as an oncogene in murine hematopoiesis, was
recently implicated in murine calvarial osseous develop-
ment, facial membranous bone ossification, and palatal
development [36-38]. Homozygous Mn1
-/- mice had cal-
varial bone defects with secondary cleft palate and died
at birth or shortly thereafter [38,39]. Heterozygous Mn1
+/- mice showed hypoplastic membranous calvarium
with incomplete penetrance of cleft palate [38], consis-
tent with the demonstrated role of Mn1 in maintaining
maturation and function of calvarial osteoblasts [40].
Furthermore, Mn1 is a transcriptional activator that reg-
ulates expression of Tbx22 during palatal development
in mice [39]. Loss of murine Tbx22,w h i c hr e g u l a t e s
intramembranous bone formation in the posterior hard
palate, causes submucosal cleft palate with ankyloglossia
in mice [41]. Importantly, TBX22 was recently also
implicated in cleft palate formation in humans in that
up to 5% of children with non-syndromic cleft palate
have mutations in TBX22 [42], and TBX22 loss in
humans is associated with X-linked cleft palate with
ankyloglossia (CPX) [43]. Interestingly, the six patients
we identified with MN1 deletion (Figure 3, Table 1) all
had either craniofacial dysmorphism and/or palatal
defects. Taken together, this suggests that loss of MN1
in these six patients may be the underlying cause for, or
contributing factor to, their craniofacial dysmorphism
and/or cleft palate, and supports investigation of a role
for MN1 in human craniofacial dysmorphism and/or
cleft palate.
Conclusions
This is the first report of association between haploin-
sufficiency of the human MN1 gene (a gene associated
with murine craniofacial development) and human cra-
niofacial malformations, supporting a more in-depth
investigation of a role for MN1 in human craniofacial
development. Additionally, the overlapping phenotype of
the patients described here suggests that a 22q12.2-con-
tiguous gene deletion syndrome should be considered in
individuals with hearing loss, developmental deficits and
craniofacial dysmorphism that includes Pierre-Robin
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Page 6 of 8Sequence or isolated micrognathia with or without cleft
palate. As microarray testing replaces chromosome and
FISH testing, large deletions such as the one found in
our patient are more likely to be found when interrogat-
ing cases of PRS. This may allow earlier diagnosis of
similar contiguous gene deletions and provide for earlier
surveillance of serious clinical disorders such as NF2.
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Written informed permission for use and disclosure of
this patient’s protected health information for research
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